Skip to content
Screener

EyePoint, Inc. EYPT EBITDA margin

EBITDA margin at other companies

Merck & Co. logo
Merck & Co.MRK
13.7%-19.7pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
28.1%-2.5pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-566.5%+1,247pp
Regenxbio logo
RegenxbioRGNX
-85.3%-8.2pp
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
-214.6%-107pp
HRO
HarrowHROW
-0.3%-7.5pp

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.13B+59.1%
Enterprise value$1.04B+57.2%
P/S404×+390×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Calculated from EyePoint, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037

FAQ

What is EyePoint, Inc.'s EBITDA margin?
EyePoint, Inc. (EYPT) reported EBITDA margin of -11,272% in Q2 2026.
How has EyePoint, Inc.'s EBITDA margin changed year-over-year?
EyePoint, Inc.'s EBITDA margin decreased by 3024.2% year-over-year, from -360.8% to -11,272%.
What is the long-term trend for EyePoint, Inc.'s EBITDA margin?
Over 5 years (2020 to 2025), EyePoint, Inc.'s EBITDA margin has grown at a 50.2% compound annual growth rate (CAGR), from -100.6% to -768.6%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.

Ask your AI about EyePoint, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude